Term
Advate
Helixate
Kogenate
Recombinate |
|
Definition
Human derived or recombinant FVIII concentrates
Used in the treatment of Hemophilia A
Formation of antibodies limit their utility |
|
|
Term
|
Definition
Human derived or recombinant IX concentrate
Used in the treatment of Hemophilia B
Formation of antibodies limit their utility |
|
|
Term
|
Definition
Blood product containing concentrated fibrinogen and other clotting factors
Used in the treatment of fibrinogen disorders |
|
|
Term
|
Definition
Acts via vasopressin V2 receptors to increase cAMP and promote vWF release
Used in the treatment of von Willebrand disease (vWD) |
|
|
Term
|
Definition
Lyophilized concentrate of purified vWF and FVIII that also contains fibrinogen and albumin
Used in the treatment of von Willebrand disease when DDAVP is inadequate |
|
|
Term
|
Definition
Glycosaminoglycan
Augment rate of anti-thrombin inactivation of thromin & other clotting factors
Used in the treatment of anti-thrombin deficiency
LMW is more selective for Xa than IIa
Adverse effects include bleeding, allergic reactions, thrombocytopenia |
|
|
Term
|
Definition
Inhibits the enzyme Vitamin K epoxyde reductase and reduces liver content of vitamin K (essential for gamma-carboxylation and activation of clotting factors)
Slow onset, long half-life, many food-drug interactions
Narrow therapeutic window |
|
|
Term
Rivaroxaban
Apixaban
Edoxaban
Betrixaban |
|
Definition
Oral direct factor Xa inhibitors
Anticoagulants
Rapid onset, short half-life
No direct antidotes |
|
|
Term
|
Definition
Oral direct factor IIa inhibitors
Anticoagulants
Rapid onset, short half-life
No direct antidotes |
|
|
Term
|
Definition
Irreversible cyclooxygenase inhibitor
Antithrombotic (anti-platelet) agent |
|
|
Term
Clopidogrel (Plavix)
Prasugrel (Efficent)
Ticagrelor (Brilinta)
Ticlopidine (Ticlid) |
|
Definition
Adenosine diphosphate 9ADP) receptor inhibitors
Antithrombotic (anti-platelet) agent
Prasugrel > clopidogrel |
|
|
Term
|
Definition
Phosphodiesterase inhibitor
Antithrombotic (anti-platelet) agent
Inhibits cAMP breakdown by PDE3A in platelets |
|
|
Term
Abciximab (ReoPro)
Eptifibatide (Integrilin)
Tirofiban (Aggrastat) |
|
Definition
Glycoprotein IIB/IIIA inhibitors
Antithrombotic (anti-platelet) agent
Antibodies react with glycoprotein on platelets & antagonize their binding to collagen at sites of vascular damage |
|
|
Term
| Dipyridamole (Persantine) |
|
Definition
Adenosine reuptake inhibitor
Antithrombotic (anti-platelet) agent
Increases circulating adenosine which binds to adenosine receptors and inhibits platelet aggregation by increases platelet cAMP synthesis |
|
|
Term
|
Definition
| Thromboxane receptor antagonists |
|
|
Term
| Urokinase (uPA, Abbokinase) |
|
Definition
Profibrinolytic agent
Human enzyme synthesized in the kidney
Directly converts plasminogen to plasmin
High antigenicity |
|
|
Term
|
Definition
Profibrinolytic agent
Protein synthezied by Streptococci
Activates with an activator of plasminogen to yield plasmin
High antigenicity |
|
|
Term
| Tissue plasminogen activator (tPA) |
|
Definition
Profibrinolytic agent
Initially isolated from melanoma tumour cell line
Directly promotes the conversion of plaminogen to plasmin
Selective for fibrin-bound plasminogen
Low antigenicity |
|
|
Term
|
Definition
Profibrinolytic agents
Recombinant tissue plasminogen activator |
|
|
